临床研究gydF4y2Ba
Spondyloarthropathies在自身免疫性疾病,反之亦然gydF4y2Ba
表2gydF4y2Ba
水疗患者的一般特征。gydF4y2Ba
|
|
经典的分类(gydF4y2Ba2gydF4y2Ba]gydF4y2Ba |
|
新的分类(gydF4y2Ba3gydF4y2Ba,gydF4y2Ba4gydF4y2Ba]gydF4y2Ba |
|
|
(gydF4y2Ba)gydF4y2Ba一个gydF4y2Ba |
作为gydF4y2Ba
(gydF4y2Ba)gydF4y2Ba |
PsAgydF4y2Ba
(gydF4y2Ba)gydF4y2Ba |
uSpA (gydF4y2Ba)gydF4y2Ba |
IBD-associated SpA (gydF4y2Ba)gydF4y2Ba |
|
轴向(gydF4y2Ba)gydF4y2Ba |
外围(gydF4y2Ba)gydF4y2Ba |
|
|
| 意思是(SD)gydF4y2Ba |
|
|
|
|
|
|
|
|
|
|
| 年龄、年gydF4y2Ba |
43.78 (11.08)gydF4y2Ba |
42.23 (10.33)gydF4y2Ba |
50.81 (13.00)gydF4y2Ba |
41.28 (8.45)gydF4y2Ba |
38.96 (6.02)gydF4y2Ba |
b, cgydF4y2Ba |
41.80 (10.15)gydF4y2Ba |
46.54 (11.84)gydF4y2Ba |
|
| 在发病年龄、年gydF4y2Ba |
34.77 (11.39)gydF4y2Ba |
33.24 (10.71)gydF4y2Ba |
41.23 (11.20)gydF4y2Ba |
33.71 (11.52)gydF4y2Ba |
29.33 (6.77)gydF4y2Ba |
bgydF4y2Ba |
33.05 (10.42)gydF4y2Ba |
37.62 (12.35)gydF4y2Ba |
|
| 在诊断,岁gydF4y2Ba |
39.24 (10.98)gydF4y2Ba |
37.58 (10.27)gydF4y2Ba |
45.65 (12.43)gydF4y2Ba |
37.54 (9.31)gydF4y2Ba |
34.17 (7.83)gydF4y2Ba |
b, cgydF4y2Ba |
37.40 (10.03)gydF4y2Ba |
42.00 (11.95)gydF4y2Ba |
|
|
| 特点,gydF4y2BangydF4y2Ba(%)gydF4y2Ba |
|
|
|
|
|
|
|
|
|
|
| 百分比gydF4y2Ba |
One hundred.gydF4y2Ba |
55.6gydF4y2Ba |
21.5gydF4y2Ba |
16.7gydF4y2Ba |
4.2gydF4y2Ba |
NAgydF4y2Ba |
60.13gydF4y2Ba |
37.16gydF4y2Ba |
NAgydF4y2Ba |
| 男性gydF4y2BadgydF4y2Ba |
82 (56.9)gydF4y2Ba |
45 (56.3)gydF4y2Ba |
20 (64.5)gydF4y2Ba |
13 (54.2)gydF4y2Ba |
2 (33.3)gydF4y2Ba |
NSgydF4y2Ba |
51 (57.39)gydF4y2Ba |
31 (56.4)gydF4y2Ba |
NSgydF4y2Ba |
| 女gydF4y2Ba |
62 (43.1)gydF4y2Ba |
35 (43.8)gydF4y2Ba |
11 (35.5)gydF4y2Ba |
11 (45.8)gydF4y2Ba |
4 (66.7)gydF4y2Ba |
NSgydF4y2Ba |
38 (42.7)gydF4y2Ba |
24 (43.6)gydF4y2Ba |
NSgydF4y2Ba |
| 腰痛gydF4y2Ba |
111 (77.1)gydF4y2Ba |
80 (100)gydF4y2Ba |
10 (32.3)gydF4y2Ba |
15 (62.5)gydF4y2Ba |
4 (66.7)gydF4y2Ba |
b, c, egydF4y2Ba |
89 (100)gydF4y2Ba |
50 (90.9)gydF4y2Ba |
|
| 外周关节炎gydF4y2Ba |
73 (50.7)gydF4y2Ba |
22日(27.5)gydF4y2Ba |
24 (77.4)gydF4y2Ba |
22日(91.7)gydF4y2Ba |
3 (50)gydF4y2Ba |
b, cgydF4y2Ba |
23日(25.8)gydF4y2Ba |
50 (90.9)gydF4y2Ba |
|
| Enthesitis(脚跟)gydF4y2Ba |
26日(18.1)gydF4y2Ba |
18 (22.5)gydF4y2Ba |
2 (6.5)gydF4y2Ba |
4 (16.7)gydF4y2Ba |
2 (33.3)gydF4y2Ba |
NSgydF4y2Ba |
20 (22.5)gydF4y2Ba |
6 (10.9)gydF4y2Ba |
NSgydF4y2Ba |
| Enthesitis(其他网站)gydF4y2Ba |
34 (23.6)gydF4y2Ba |
19日(23.8)gydF4y2Ba |
6 (16.1)gydF4y2Ba |
8 (33.3)gydF4y2Ba |
2 (33.3)gydF4y2Ba |
NSgydF4y2Ba |
22日(24.7)gydF4y2Ba |
12 (21.8)gydF4y2Ba |
NSgydF4y2Ba |
| 指炎gydF4y2Ba |
28日(19.4)gydF4y2Ba |
10 (12.5)gydF4y2Ba |
9 (29)gydF4y2Ba |
8 (33.3)gydF4y2Ba |
1 (16.7)gydF4y2Ba |
NSgydF4y2Ba |
11 (12.4)gydF4y2Ba |
17 (30.9)gydF4y2Ba |
|
| 牛皮癣gydF4y2Ba |
28日(19.4)gydF4y2Ba |
0gydF4y2Ba |
28日(90.3)gydF4y2Ba |
0gydF4y2Ba |
0gydF4y2Ba |
b, f, ggydF4y2Ba |
2 (2.2)gydF4y2Ba |
26日(47.3)gydF4y2Ba |
|
| 炎症性肠病gydF4y2Ba |
6 (4.2)gydF4y2Ba |
0gydF4y2Ba |
0gydF4y2Ba |
0gydF4y2Ba |
6 (100)gydF4y2Ba |
e, g, hgydF4y2Ba |
2 (2.2)gydF4y2Ba |
4 (7.3)gydF4y2Ba |
NSgydF4y2Ba |
|
| HLA-B27gydF4y2Ba |
|
|
|
|
|
|
|
|
|
|
| 积极的gydF4y2Ba |
43/86 (50)gydF4y2Ba |
27/54 (50)gydF4y2Ba |
2/11 (18.2)gydF4y2Ba |
14/17 (82.35)gydF4y2Ba |
0gydF4y2Ba |
NAgydF4y2Ba |
29/59 (49.15)gydF4y2Ba |
14/27 (51.85)gydF4y2Ba |
NAgydF4y2Ba |
| 负gydF4y2Ba |
43/86 (50)gydF4y2Ba |
27/54 (50)gydF4y2Ba |
9/11 (81.8)gydF4y2Ba |
3/17 (17.65)gydF4y2Ba |
2/2 (100)gydF4y2Ba |
NAgydF4y2Ba |
30/59 (50.85)gydF4y2Ba |
13/27 (48.15)gydF4y2Ba |
NAgydF4y2Ba |
| 没有数据可用gydF4y2Ba |
58/144 (40.3)gydF4y2Ba |
26/80 (32.5)gydF4y2Ba |
20/31 (64.5)gydF4y2Ba |
7/24 (29.16)gydF4y2Ba |
4/6 (66.66)gydF4y2Ba |
NAgydF4y2Ba |
30/89 (33.7)gydF4y2Ba |
28/55 (50.9)gydF4y2Ba |
NAgydF4y2Ba |
|
|
强直性脊柱炎、PsA:银屑病关节炎,uSpA:未分化的spondyloarthropatty,炎症性肠病:炎症性肠病,意图:反应性关节炎、广告:自身免疫性疾病,HLA:人类白细胞抗原,NA:不适用,与NS:非显著。gydF4y2Ba
一个gydF4y2Ba无论是ReA (gydF4y2Ba)和独家extraarticular温泉都包括在内。gydF4y2Ba
bgydF4y2Ba,PsA之间的显著差异。gydF4y2Ba
cgydF4y2Ba作为和uSpA之间的显著差异。gydF4y2Ba
dgydF4y2Ba为所有类别显著的性别差异。gydF4y2Ba
egydF4y2Ba之间的显著差异,IBD-associated温泉。gydF4y2Ba
fgydF4y2BaPsA和uSpA之间有着显著的不同。gydF4y2Ba
ggydF4y2BaPsA和IBD-associated SpA之间有着显著的不同。gydF4y2Ba
hgydF4y2BauSpA之间的显著差异和IBD-associated SpA。gydF4y2Ba
|
